semaglutide fatty liver Novo's trial of weight-loss drug shows improvement in disease Semaglutide Shows Promise for Fatty

Ozempic, WeGovy, and Mounjaro

Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist CT-388 achieved substantial, sustained, and dose-dependent weight loss through 48 weeks

Although there were no differences in magnitude between conditions (P>0.11), the postprandial GLP-1 peak response to breakfast intake was delayed by 90min following sleep loss in comparison with regular sleep (P<0.02)

GLP-1 treatments are being found to provide health benefits beyond weight loss, which could drive sales

Joshua Baker offers cutting-edge, medically supervised weight loss solutions to help you achieve lasting

Gastroparesis is characterized by delayed gastric emptying, with symptoms such as nausea, vomiting and abdominal pain, in the absence of mechanical obstruction